Share to: share facebook share twitter share wa share telegram print page

Lapisteride

Lapisteride
Clinical data
Routes of
administration		Oral[1]
ATC code
  • None
Legal status
Legal status
  • In general: non-regulated
Identifiers
  • N-[1-(4-methoxyphenyl)-1-methylethyl]-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC29H40N2O3
Molar mass464.650 g·mol−1
3D model (JSmol)
  • O=C(NC(c1ccc(OC)cc1)(C)C)[C@@H]3[C@]2(CC[C@H]4[C@H]([C@@H]2CC3)CC[C@H]5NC(=O)\C=C/[C@]45C)C
  • InChI=1S/C29H40N2O3/c1-27(2,18-6-8-19(34-5)9-7-18)31-26(33)23-12-11-21-20-10-13-24-29(4,17-15-25(32)30-24)22(20)14-16-28(21,23)3/h6-9,15,17,20-24H,10-14,16H2,1-5H3,(H,30,32)(H,31,33)/t20-,21-,22-,23+,24+,28-,29+/m0/s1 checkY
  • Key:NAGKTIAFDQEFJI-DPMIIFTQSA-N checkY
  (verify)

Lapisteride (INN; CS-891) is a dual inhibitor of both isoforms of the enzyme 5α-reductase.[2] It was under investigation for the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia,[2][3] but was never marketed.

See also

References

  1. ^ Yada S, Ohya M, Ohuchi Y, Hamaura T, Wakiyama N, Usui F, et al. (April 2003). "Solid phase transition of CS-891 enantiotropes during grinding". International Journal of Pharmaceutics. 255 (1–2): 69–79. doi:10.1016/S0378-5173(03)00084-X. PMID 12672603.
  2. ^ a b Niiyama S, Kojima K, Hamada T, Happle R, Hoffmann R (December 2000). "The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles". European Journal of Dermatology. 10 (8): 593–595. PMID 11125319.
  3. ^ Bernan; British Pharmacopoeia Commission (February 2002). British Approved Names 2002. The Stationery Office. p. 157. ISBN 978-0-11-322558-3. Retrieved 17 November 2011.
Kembali kehalaman sebelumnya